For dividend investors seeking defensive healthcare names, Johnson & Johnson (JNJ) and Kenvue (KVUE) are two companies that cannot be overlooked. A natural question arises: Which one is more deserving of a place in a dividend portfolio? Comparing metrics such as dividend yield and payout ratio alone is not enough; factors including acquisitions, legal settlements, and corporate growth trajectories can all complicate the picture.
Johnson & Johnson is a favorite among dividend growth investors. As a “Dividend King,” it has raised its dividend for more than 50 consecutive years. In 2026, the company will mark its 64th consecutive year of annual dividend increases, lifting its annual payout to $5.36 per share, corresponding to a forward dividend yield of about 2%. After spinning off its consumer health business (now Kenvue), Johnson & Johnson has become a pure-play pharmaceutical and medical technology company, focused on faster-growing, higher-margin but also riskier areas such as oncology, immunology, and surgical instruments.
However, how high are the risks really? Litigation is one of the company’s biggest concerns, especially the long-running claims that its talc-based baby powder caused ovarian cancer and mesothelioma. The proposed $5.5 billion settlement for ovarian cancer claims has yet to reach the 95% participation threshold, while mesothelioma cases are still being litigated one by one. As of the second quarter of 2026, Johnson & Johnson had reserved approximately $3.7 billion for talc-related liabilities. This means that this reliable dividend payer carries a heavy legal burden, and settlements could erode cash that might otherwise be used for dividends, research and development, or acquisitions.
Meanwhile, the stock trades at a price-to-earnings ratio of about 31 times, above the industry average of 25 times. Nevertheless, the consensus of 25 analysts still assigns it a “Moderate Buy” rating, with a highest price target of $320, suggesting that Wall Street sees upside from current levels.
As the company spun off from Johnson & Johnson, Kenvue often appears on lists of “Dividend Kings,” because if its years as part of Johnson & Johnson are included, its 64 consecutive years of increases meet the standard. Currently, the company pays an annual dividend of $0.84 per share, for a forward dividend yield of 4.71%, and its stock is cheaper, with a price-to-earnings ratio of about 21 times.
Unlike Johnson & Johnson, Wall Street analysts have a consensus rating of “Hold” on Kenvue, with an average price target of $19. Part of the reason lies in its business itself: the company owns mature, slow-growing consumer staples brands such as Tylenol, Band-Aid, and Listerine. Every household needs them, but once daily demand matures, revenue growth begins to stall. A more important reason is that Kenvue may not remain an independent dividend stock for much longer. In November 2025, Kimberly-Clark agreed to acquire Kenvue in a cash-and-stock deal valued at approximately $48.7 billion. This changes the logic of the story: buying Kenvue now means betting in advance on the proposed acquisition, while the combined company’s financial condition, business risks, and dividend outlook all remain uncertain.
Holding Kenvue is more like a gamble on the completion of the acquisition, essentially a bet on Kimberly-Clark’s dividend. By contrast, Johnson & Johnson’s dividend history speaks for itself. Despite billions of dollars in legal liabilities on its books, the company still has sufficient cash flow and a diversified business model to continue raising its dividend.
